Skip to content

This website is a third-party information service. It does not provide medical care or operate a treatment facility.

CNS Medication Trials

San Diego, California

CNS medication trials in San Diego, CA

25 CNS medication studies are recruiting participants at sites in San Diego as of November 17, 2026, according to ClinicalTrials.gov. CNS Medication Trials can help you understand your options and connect with a study team.

Call (888) 927-5768
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

San Diego at a glance

  • 25 studies are recruiting at a site in San Diego.
  • By phase: Phase 2 (8), Phase 3 (15), Phase 4 (2).
  • By sponsor: industry (23), university, hospital or other (2).
  • By research area: Depression (11), Schizophrenia (7), Migraine (4), Epilepsy (2), Bipolar Disorder (1).
  • Most recent update to one of these records: November 12, 2026.

Depression studies recruiting in San Diego

Basic details from each study's public record. Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses

    • Phase 2
    • Ages 18 to 80
    • All sexes
    Sponsor
    Reunion Neuroscience Inc
    Study site
    Kadima Neuropsychiatry Institute
    Registry record
    NCT07002034 · updated
  2. A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)

    • Phase 3
    • Ages 18 to 74
    • All sexes
    Sponsor
    Definium Therapeutics US, Inc.
    Study site
    Kadima Neuropsychiatry Institute
    Registry record
    NCT07592689 · updated
  3. A Study of Esketamine Nasal Spray Versus Placebo Spray in Adult Participants With Treatment-resistant Depression

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Janssen Research & Development, LLC
    Study site
    Artemis Institute for Clinical Research
    Registry record
    NCT07716098 · updated
  4. Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Neurocrine Biosciences
    Study site
    Neurocrine Clinical Site
    Registry record
    NCT06966401 · updated
  5. A Study to Evaluate TNX-102 SL Monotherapy Versus Placebo in Participants With Major Depressive Disorder (MDD)

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Tonix Pharmaceuticals, Inc.
    Registry record
    NCT07621237 · updated
  6. ALTO-207 in Adults With Treatment-resistant Depression (TRD)

    • Phase 2
    • Ages 18 to 75
    • All sexes
    Sponsor
    Alto Neuroscience
    Registry record
    NCT07553637 · updated
  7. Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol

    • Phase 3
    • Ages 18 to 65
    • All sexes
    Sponsor
    Axsome Therapeutics, Inc.
    Registry record
    NCT07484217 · updated
  8. A Study to Evaluate the Effectiveness of DT-101 in Patients With Depression

    • Phase 2
    • Ages 18 to 75
    • All sexes
    Sponsor
    Draig Therapeutics Ltd
    Study site
    Draig Clinical Site
    Registry record
    NCT07300969 · updated
  9. A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor

    • Phase 4
    • Ages 18 and older
    • All sexes
    Sponsor
    Neurocrine Biosciences
    Study site
    Neurocrine Clinical Site
    Registry record
    NCT07105111 · updated
  10. Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Neurocrine Biosciences
    Study site
    Neurocrine Clinical Site
    Registry record
    NCT06786624 · updated
  11. A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms

    • Phase 4
    • Ages 18 to 65
    • All sexes
    Sponsor
    Axsome Therapeutics, Inc.
    Registry record
    NCT06223880 · updated

Source: ClinicalTrials.gov. Data processed . See every depression study recruiting in San Diego, CA on ClinicalTrials.gov.

Schizophrenia studies recruiting in San Diego

  1. A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis

    • Phase 2
    • Ages 55 to 90
    • All sexes
    Sponsor
    MapLight Therapeutics
    Registry record
    NCT06887192 · updated
  2. A Long-Term Open-Label Study of ML-007C-MA in Adults With Schizophrenia

    • Phase 2
    • Ages 18 to 65
    • All sexes
    Sponsor
    MapLight Therapeutics
    Registry record
    NCT07459647 · updated
  3. NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia

    • Phase 3
    • Ages 18 to 65
    • All sexes
    Sponsor
    Neurocrine Biosciences
    Study site
    Neurocrine Clinical Site
    Registry record
    NCT07114874 · updated
  4. 52-week Open Label Safety-Tolerability Study

    • Phase 3
    • Ages 18 to 65
    • All sexes
    Sponsor
    LB Pharmaceuticals Inc.
    Study site
    Synergy San Diego
    Registry record
    NCT07369154 · updated
  5. NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia

    • Phase 3
    • Ages 18 to 65
    • All sexes
    Sponsor
    Neurocrine Biosciences
    Study site
    Neurocrine Clinical Site
    Registry record
    NCT06963034 · updated
  6. Randomized Withdrawal Study in Patients With Schizophrenia

    • Phase 3
    • Ages 18 to 65
    • All sexes
    Sponsor
    Vanda Pharmaceuticals
    Study site
    Vanda Investigational Site
    Registry record
    NCT06961968 · updated
  7. Effects of Cannabidiol (CBD) Versus Placebo as an Adjunct to Treatment in Early Psychosis

    • Phase 3
    • Ages 16 to 30
    • All sexes
    Sponsor
    University of California, San Diego
    Study site
    University of California, San Diego
    Registry record
    NCT04411225 · updated

Source: ClinicalTrials.gov. Data processed . See every schizophrenia study recruiting in San Diego, CA on ClinicalTrials.gov.

Bipolar disorder studies recruiting in San Diego

  1. An Assessment of Efficacy, Safety, and Pharmacokinetics of NBI-1117568 in Adults With Bipolar I Disorder With Current Mania

    • Phase 2
    • Ages 18 to 65
    • All sexes
    Sponsor
    Neurocrine Biosciences
    Study site
    Neurocrine Clinical Site
    Registry record
    NCT07288320 · updated

Source: ClinicalTrials.gov. Data processed . See every bipolar disorder study recruiting in San Diego, CA on ClinicalTrials.gov.

Epilepsy studies recruiting in San Diego

  1. A Fully Remote Feasibility Trial of Phenylbutyrate for SLC6A1-Related Disorders

    • Phase 2
    • Ages 2 to 60
    • All sexes
    Sponsor
    Scripps Translational Science Institute
    Study site
    Scripps Research Translational Institute
    Registry record
    NCT07847918 · updated
  2. A Clinical Trial of Elsunersen in Pediatric SCN2A-DEE to Assess Efficacy and Safety

    • Phase 3
    • From 1 day, up to 18 years
    • All sexes
    Sponsor
    Praxis Precision Medicines
    Study site
    Praxis Research Site
    Registry record
    NCT07019922 · updated

Source: ClinicalTrials.gov. Data processed . See every epilepsy study recruiting in San Diego, CA on ClinicalTrials.gov.

Migraine studies recruiting in San Diego

  1. A Study to Assess the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine

    • Phase 3
    • Ages 18 to 75
    • All sexes
    Sponsor
    TriGemX Bio, Inc.
    Study site
    Paradigm Clinical Research Centers, LLC
    Registry record
    NCT07816367 · updated
  2. A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine

    • Phase 3
    • Ages 18 to 75
    • All sexes
    Sponsor
    TriGemX Bio, Inc.
    Study site
    Acclaim Clinical Research
    Registry record
    NCT07645924 · updated
  3. A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    TriGemX Bio, Inc.
    Study site
    Acclaim Clinical Research
    Registry record
    NCT07674654 · updated
  4. Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)

    • Phase 3
    • Ages 6 to 17
    • All sexes
    Sponsor
    AbbVie
    Study site
    Paradigm Clinical Research - San Diego /ID# 269608
    Registry record
    NCT05125302 · updated

Source: ClinicalTrials.gov. Data processed . See every migraine study recruiting in San Diego, CA on ClinicalTrials.gov.

Ask about studies near San Diego

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

More locations in California

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 17, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that test a medication, as each study is coded in the registry.

CNS Medication Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 927-5768

or send a short form

How should we reach you?

Call